目的:探讨siRNA抑制TGFβ3诱发腭裂的机制。方法:使用不同剂量(200、400、800pmol)经脂质体LipofectamineTM2000包裹的TGFβ3 StealthTMRNAi于交配后(days post coitum,dpc)12天做孕鼠宫腔注射,等体积生理盐水注射作为空白对照。14dpc...目的:探讨siRNA抑制TGFβ3诱发腭裂的机制。方法:使用不同剂量(200、400、800pmol)经脂质体LipofectamineTM2000包裹的TGFβ3 StealthTMRNAi于交配后(days post coitum,dpc)12天做孕鼠宫腔注射,等体积生理盐水注射作为空白对照。14dpc时取部分胎鼠腭突,RT-PCR及Western印迹检测腭突中TGFβ3、Smad2、BMP2的表达情况。16dpc时再取部分胎鼠腭突,观察腭突融合情况,免疫组织化学及免疫荧光观察胚鼠腭突的TGFβ3、Smad2、BMP2的表达情况。实验数据均以SPSS13.0软件包进行分析,多组间比较采用单因素方差分析,两组间比较采用t检验。结果:宫腔注射800pmol的StealthTMRNAi,可引起TGFβ3基因mRNA和蛋白表达水平明显降低,400pmol组能显著降低Smad2基因的mRNA和蛋白表达水平,但BMP2的表达情况未受明显影响。20%～60%的实验组小鼠胚胎腭突不能融合,形成腭隐裂,与空白对照组相比,其TGFβ3、Smad2的表达量较低,而BMP2的表达未见显著变化。结论:在12dpc给予小鼠宫腔注射TGFβ3 StealthTMRNAi,能有效沉默TGFβ3基因,20%～60%小鼠胚胎形成腭隐裂,同时Smad2基因表达下调,但对BMP2基因表达无明显影响。展开更多
Resorption and loss of alveolar bone leads to oral dysfunction and loss of natural or implant teeth. Biomimetic delivery of growth factors based on stem cell recruitment and osteogenic differentiation, as the key step...Resorption and loss of alveolar bone leads to oral dysfunction and loss of natural or implant teeth. Biomimetic delivery of growth factors based on stem cell recruitment and osteogenic differentiation, as the key steps in natural alveolar bone regenerative process, has been an area of intense research in recent years. A mesoporous self-healing hydrogel(DFH) with basic fibroblast growth factor(bFGF) entrapment and transforming growth factor β3(TGFβ3)-loaded chitosan microspheres(CMs) was developed. The formulation was optimized by multiple tests of self-healing, in-bottle inversion, SEM, rheological, swelling rate and in vitro degradation. In vitro tubule formation assays, cell migration assays, and osteogenic differentiation assays confirmed the ability of DFH to promote blood vessels, recruit stem cells, and promote osteogenic differentiation. The optimum DFH formula is 0.05 ml 4ArmPEG-DF(20%) added to 1 ml CsGlu(2%) containing bFGF(80 ng) and TGFβ3-microspheres(5 mg). The results of in vitro release studied by Elisa kit, indicated an 95% release of b FGF in7 d and long-term sustained release of TGFβ3. For alveolar defects rat models, the expression levels of CD29 and CD45, the bone volume fraction, trabecular number, and trabecular thickness of new bone monitored by Micro-CT in DFH treatment groups were significantly higher than others(*P < 0.05, vs Model). HE and Masson staining show the same results.In conclusion, DFH is a design of bionic alveolar remodelling microenvironment, that is in early time microvessels formed by b FGF provide nutritious to recruited endogenous stem cells, then TGFβ3 slowly released speed up the process of new bones formation to common facilitate rat alveolar defect repair. The DFH with higher regenerative efficiency dovetails nicely with great demand due to the requirement of complicated biological processes.展开更多
文摘目的:探讨siRNA抑制TGFβ3诱发腭裂的机制。方法:使用不同剂量(200、400、800pmol)经脂质体LipofectamineTM2000包裹的TGFβ3 StealthTMRNAi于交配后(days post coitum,dpc)12天做孕鼠宫腔注射,等体积生理盐水注射作为空白对照。14dpc时取部分胎鼠腭突,RT-PCR及Western印迹检测腭突中TGFβ3、Smad2、BMP2的表达情况。16dpc时再取部分胎鼠腭突,观察腭突融合情况,免疫组织化学及免疫荧光观察胚鼠腭突的TGFβ3、Smad2、BMP2的表达情况。实验数据均以SPSS13.0软件包进行分析,多组间比较采用单因素方差分析,两组间比较采用t检验。结果:宫腔注射800pmol的StealthTMRNAi,可引起TGFβ3基因mRNA和蛋白表达水平明显降低,400pmol组能显著降低Smad2基因的mRNA和蛋白表达水平,但BMP2的表达情况未受明显影响。20%～60%的实验组小鼠胚胎腭突不能融合,形成腭隐裂,与空白对照组相比,其TGFβ3、Smad2的表达量较低,而BMP2的表达未见显著变化。结论:在12dpc给予小鼠宫腔注射TGFβ3 StealthTMRNAi,能有效沉默TGFβ3基因,20%～60%小鼠胚胎形成腭隐裂,同时Smad2基因表达下调,但对BMP2基因表达无明显影响。
基金supported by grants from the Guangzhou Science and Technology Program Key Project(Grant No.201803010044)Guangdong Province College Characteristic Innovation Project(2019KTSCX011)+2 种基金Guangdong Province Natural Sciences Fund Project(2021A1515012480)the Key Areas Research and Development Program of Guangzhou(202103030003)Guangdong Province Special Fund Projects(Yueziranzihe,2021,No.50).
文摘Resorption and loss of alveolar bone leads to oral dysfunction and loss of natural or implant teeth. Biomimetic delivery of growth factors based on stem cell recruitment and osteogenic differentiation, as the key steps in natural alveolar bone regenerative process, has been an area of intense research in recent years. A mesoporous self-healing hydrogel(DFH) with basic fibroblast growth factor(bFGF) entrapment and transforming growth factor β3(TGFβ3)-loaded chitosan microspheres(CMs) was developed. The formulation was optimized by multiple tests of self-healing, in-bottle inversion, SEM, rheological, swelling rate and in vitro degradation. In vitro tubule formation assays, cell migration assays, and osteogenic differentiation assays confirmed the ability of DFH to promote blood vessels, recruit stem cells, and promote osteogenic differentiation. The optimum DFH formula is 0.05 ml 4ArmPEG-DF(20%) added to 1 ml CsGlu(2%) containing bFGF(80 ng) and TGFβ3-microspheres(5 mg). The results of in vitro release studied by Elisa kit, indicated an 95% release of b FGF in7 d and long-term sustained release of TGFβ3. For alveolar defects rat models, the expression levels of CD29 and CD45, the bone volume fraction, trabecular number, and trabecular thickness of new bone monitored by Micro-CT in DFH treatment groups were significantly higher than others(*P < 0.05, vs Model). HE and Masson staining show the same results.In conclusion, DFH is a design of bionic alveolar remodelling microenvironment, that is in early time microvessels formed by b FGF provide nutritious to recruited endogenous stem cells, then TGFβ3 slowly released speed up the process of new bones formation to common facilitate rat alveolar defect repair. The DFH with higher regenerative efficiency dovetails nicely with great demand due to the requirement of complicated biological processes.
